Compare PLMR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLMR | TLX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2019 | 2024 |
| Metric | PLMR | TLX |
|---|---|---|
| Price | $136.68 | $11.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $153.60 | $21.13 |
| AVG Volume (30 Days) | ★ 177.5K | 122.3K |
| Earning Date | 05-06-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.04 | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $875,967,000.00 | N/A |
| Revenue This Year | $192.25 | N/A |
| Revenue Next Year | $19.34 | N/A |
| P/E Ratio | ★ $38.70 | $150.33 |
| Revenue Growth | ★ 58.16 | N/A |
| 52 Week Low | $100.81 | $6.28 |
| 52 Week High | $147.62 | $12.48 |
| Indicator | PLMR | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 55.51 |
| Support Level | $116.49 | $10.12 |
| Resistance Level | $140.88 | $12.35 |
| Average True Range (ATR) | 3.54 | 0.23 |
| MACD | 0.51 | -0.06 |
| Stochastic Oscillator | 95.92 | 56.85 |
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.